MedTrace Logo

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

NCT07794670 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-08-31

No results posted yet for this study

Summary

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Conditions

  • Preclinical Alzheimer's Disease

Interventions

DRUG

Obicetrapib 10 mg

once daily 10 mg Obicetrapib tablet

DRUG

Matching placebo tablets

matching placebo tablet

Sponsors & Collaborators

  • NewAmsterdam Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-09-30
Completion
2029-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07794670 on ClinicalTrials.gov